Please Wait...

Classic Blog

Quantitative Imaging Biomarkers Alliance

Improving the Use of Imaging Biomarkers in Clinical Trials

  • 0
  • 30 Jun
One of the areas I spend time on is attending working groups and scientific meetings designed to improve the use of quantitative imaging biomarkers in clinical trials. One such group is the Quantitative Imaging Biomarkers Alliance (QIBA) that is organized by the Radiological Society of North America (RSNA). Established in 2008, QIBA includes representatives from pharmaceutical companies, imaging equipment manufacturers, government agencies, professional societies and clinical trial centers.
Read More

Technology for Clinical Trial Supply Planning

  • 0
  • 25 Jun
The 2010 Optimizer User Conference recently ended and I am happy to report a surge in discussion around technology for clinical trial supply planning. I think this speaks well to the growth of the Optimizer product and greater acceptance of the application of more sophisticated tools to the clinical supply planning process in general. There were a number of roundtable discussions and open training sessions, which were as valuable for me as I believe they were for the attendees.
Read More

The Future Development of Imaging Biomarkers

  • 0
  • 22 Jun
An imaging biomarker is a quantifiable anatomic, physiologic or metabolic parameter derived from an image that is an indicator of a particular disease. Furthermore a biomarker is a parameter which can be used at an indicator of the progression of a disease or medical condition or the effect of treatment. A number of public-private partnerships are working together to develop novel imaging biomarkers. One of these is the Alzheimer's Disease Neuroimaging Initiative (ADNI). A few years ago the ADNI started a clinical trial (ADN1-1) that involved 57 sites with 200 normal subjects followed for three years, 400 subjects with mild cognitive impairment (MCI) followed for 2 years and 200 subjects with Alzheimer's disease (AD) followed for 2 years. Participants receive clinical exams, cognitive tests with some also having FDG-PET and PiB-PET. The aim was to gather longitudinal data over time and link early cognitive, imaging and biomarker changes to later clinical decline.
Read More

How Will the Stimulus Package Affect Clinical Research?

  • 0
  • 10 Jun

To borrow from Oprah, here is what I know for sure:

Read More

With Good Clinical Trial Technology, Why Is Data Still Double Entered?

  • 0
  • 09 Jun

That's just the first in a long series of persistent questions in the clinical trial industry. Why don't we have one consolidated place to see all information regarding a specific region, site, or patient? How come every clinical trial seems to use different terminology and disparate applications (resulting in a new learning curve and low user adoption)? Why can't we get ad-hoc reports in a format that is actually useful, covering a timeframe we actually care about?

Read More

The Use of Imaging Technologies to Improve the Flavor of Lamb

  • 0
  • 03 Jun
A few weeks ago while attending the International Osteoporosis Foundation (IOF) World Congress in Florence, I had some of the best lamb I have ever tasted at a recommended restaurant. So good, in fact, that the local chefs ate there as well at the end of their evening. It turned out the restauranteur owned a sheep farm.
Read More
Case report form CRF

Have CDISC Standards Changed the Way We Collect Data

  • 0
  • 01 Jun
CDISC Standards have drastically changed the way we collect data. How many times have we heard that the adoption of standards is a long, slow process? I'm here to tell you - I have seen the result of all of this talk about standards, and it looks like that ocean blue oasis is just peeking over the horizon. Remember all those comments on paper case report forms? In 1989, I worked on a clinical study where all the patients were HIV positive and had Pneumocystis Carinii Pneumonia (PCP). The data was vast and messy for every patient. There were pages of concomitant medications, adverse events and labs. The medical history alone was a nightmare to data enter - make that - double data enter nightmare since it was a paper-based study.
Read More

ASCO Preview Medical Imaging in Cancer Clinical Trials

  • 0
  • 26 May

The American Society of Clinical Oncology (ASCO) 2010 annual meeting starts next week in Chicago. On Tuesday, June 8 there is a joint session between ASCO and the Radiological Society of North America (RSNA) on "Imaging Informatics and Optimizing Imaging in Cancer Diagnosis."

 

American Society of Clinical Oncology ASCO

 

Read More
Top Image: Retinal Nerve Fiber Layer Analysis. Bottom Image: Macular Thickness Analysis

OCT Novel Imaging Technology Providing A Window into the Body

  • 0
  • 20 May
One emerging medical imaging technology that I have been following with interest is Optical Coherence Tomography (OCT). OCT is best described as ultrasound using light. As described by Huang et al. in a 1991 Science paper, OCT generates cross-sectional tissue images by measuring reflections from a light source. Changes in the coherence or wave structure of the reflected light, coupled with the time-delay in reflecting it, allow information on location to be generated. In this respect OCT is similar to ultrasound pulse-echo imaging. What makes OCT exciting as a diagnostic and drug development tool is that image resolution is only limited by the coherence of the light source. High resolution can, therefore, be obtained from a pinpoint light source. Add in frequency domain mapping and the ability to measure thousands of data points rapidly and you can obtain a detailed image in a matter of seconds.
Read More
FRAX iPhone app screen shot – can be used in clinical trials

FRAX iPhone app Tool to Access Fracture Risk in Clinical Trials

  • 0
  • 19 May
The iPhone continues to make inroads into all aspects of our lives, and medical imaging and clinical trials have not escaped. Doctot (Doc tools of the trade), an Irish company run by medical and software professionals, recently launched an iPhone app (priced at $5.99 in the US), which makes the WHO Fracture Risk Assessment Tool (FRAX) readily accessible to doctors.
Read More
Food and Drug Administration (FDA)

Why hasn't the FDA more actively promoted CDISC standards

  • 0
  • 18 May
It has always been a mystery to me why the FDA hasn't more enthusiastically embraced and offered incentives for NDA submissions to conform to the CDISC standards (A bit of this mystery was lifted for me at the CDISC INTRAchange in March). The INTRAchange is a meeting of the core CDISC participants and Dr. Theresa Mullin, Director of Planning and Informatics at FDA/CDER, spoke about the data review process at the FDA. The FDA uses their Janus software as a repository to store the data, but they allow the reviewers to use different end-user tools to generate their views or develop their own code for analysis purposes.
Read More
Eyjafjallajökull volcano in Iceland – Has this volcano affected your clinical trial?

Multinational Clinical Trials vs Mother Nature

  • 0
  • 17 May

We all know someone who has been impacted recently by the ash from the Eyjafjallajökull volcano in Iceland.

Source[01]: Wikipedia, photographer: Henrik Thornburn

Read More

Pages

Key Insights from SCDM Euro Leadership Forum

  • 1
  • 06 Feb

As SCDM's 2014 Chair I had the honor of presenting the keynote at the EU Leadership Forum held in The Netherlands, December 2014. Celebrating the organization's 20th Anniversary and all that's been accomplished, we took a light-hearted look at the Evolution of the Clinical Data Management Role.

Read More

Escalating Role of Medical Imaging in AD Clinical Trials

  • 0
  • 30 Jan

Alzheimer's disease is one of the most important health challenges facing aging populations worldwide. Disease modifying therapies are desperately needed and many potential treatments are currently being tested in clinical trials. The role and impact of medical imaging in AD trials continues to grow, especially as clinicians and scientists seek to define and treat AD at the earliest stages of disease.

Read More

Risk-Based Monitoring Technology: 5 Essential Capabilities

  • 0
  • 27 Jan

If you've spent time researching risk-based monitoring (RBM) over the past year, you know dozens of academics, CROs, clinical trial practitioners, and statisticians have proposed varied approaches based on sponsor needs and trial designs. Unfortunately, despite an abundance of theoretical perspectives on RBM, clinical trial teams soon discover a significant gap still exists between perspectives and actual tools to enable real-world RBM implementation.

Read More

Time to Take Action and Make Risk-Based Monitoring a Reality

  • 0
  • 19 Jan

Intense interest surrounding RBM shows alignment of all the right elements — technology, regulatory bodies and the industry itself – to make risk-based monitoring a reality. If implemented with the right components, this approach could result in the most efficient trial management possible.

Read More

Pages

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

@ArenaIntPharma pls contact our events coordinator via traditional channels
bioclinica (30 minutes ago)
eHealth Solutions president Mukhtar Ahmed speaking at #phorum17 Apr. 27 https://t.co/OaBPodxZBF https://t.co/QjHQR1LbU1
bioclinica (54 minutes ago)
Join @Bioclinica April 28 at NJ Statewide Career & Internship Fair, Rutgers Univ. https://t.co/NH3wsToDTh
bioclinica (1 hour ago)
RT @MySCRS: 96.7% of patients want to know results of #ClinicalTrials yet only 9% are able to find them after study ends. https://t.co/SxtG…
bioclinica (1 hour ago)
RT @SCDM_DataDriven: SCDM is looking for volunteers to revise the Certification Exam! Are you interested? Learn more https://t.co/X7ZYvur2fm
bioclinica (1 hour ago)
RT @ACROhealth: Follow #CTAW2017 next week to learn how more #clinicaltrial participation could help us discover better treatments. https:/…
bioclinica (1 hour ago)

Latest Blogs: